medigraphic.com

2017, Number 3

<< Back Next >>

Rev Hematol Mex 2017; 18 (3)

Invasive rhinosinusal mucormycosis after hematopoietic stem cell transplantation in a myelodysplastic syndrome patient

Gastélum-Cano JM, Motolinia-Muñoz Y, Marín-Corte JC, Ortega-Amaya ER, Gordillo-Martínez AM, Ruiz-Argüelles GJ

Language: English
References: 13
Page: 134-138
PDF size: 291.67 Kb.


ABSTRACT

Mucormycosis is a pathologic entity, caused for molds belonging to mucorales order; among risk factors are hematological malignancies, hematopoietic stem cell transplantation (HSCT) and treatment with corticosteroids. This article reports the case of a 56-year-old male patient, Mexican mestizo, with type 2 diabetes mellitus (T2DM) and class 2 obesity (BMI 37.38). As a result of pancytopenia, the bone marrow studies disclosed myeloid hyperplasia and features of myelodysplasia. An outpatient allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was performed on January 14th, 2015. After engrafting successfully, on day + 250 pancytopenia due to graft loss ensued. Then, a second outpatient allo-HSCT was made, achieving 100% chimerism. During the aplastic phase, patient developed a rhinosinusal lesion in which the causal agent was identified as Mucor sp. It is important to consider HSCT secondary mucormycosis as a risk factor in hematological malignancies patients.


REFERENCES

  1. Farmakiotis F, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 2016 Mar;30(1):143-163. doi: 10.1016/j. idc.2015.10.011

  2. Bonifaz A. Micología Médica Básica. México: McGrawHill, 2012;399-426.

  3. Tristano A, Chollet ME, Willson M, et al. Mucormicosis. Reporte de tres casos. Invest Clin 2002;43(3):183-190.

  4. García-Vidal C, Salavert-Lletí M. Inmunopatología de las micosis invasivas por hongos filamentosos. Rev Iberoam Micol 2014;31(4):219-28.

  5. Robin C, Alanio A, Cordonnier C. Mucormycosis: a new concern in the transplant ward? Curr Opin Hematol 2014 Nov;21(6):482-490. doi: 10.1097/MOH.0000000000000082

  6. Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). Clin Microbiol Infect 2012;18:E396-E400.

  7. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005-2007. Clin Microbiol Infect 2011;17:1859-1867.

  8. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveil- lance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091-1100.

  9. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009 Feb 1;48(3):265-273. doi: 10.1086/595846

  10. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917.

  11. Ruiz-Argüelles GJ, Ruiz-Delgado GJ. Fundamentos de Hematología. Editorial Médica Panamericana, 2014;143.

  12. Radsak M, Platzbecker U, Schmidt CS, Hofmann W-K, Nolte F. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Eur J Haematol 2017;99:112-118. https://doi.org/10.1111/ejh.12883

  13. Fianchi L, Leone G, Posteraro B, et al. Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. Leuk Res 2012;36:331‐333.




2020     |     www.medigraphic.com